Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use

Scandinavian Journal of Gastroenterology

Volumn 50, Issue 8, 2015, Pages 1025-1031

  Ytting, Henriette ^a   Larsen, Fin Stolze ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Alternative treatment; Autoimmune hepatitis; Everolimus; Mammalian target of rapamycin inhibitor; Nonresponse; Poor response; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BUDESONIDE; CHOLESTEROL; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLATE MOFETIL; PREDNISOLONE; TACROLIMUS; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASTHMA; AUTOIMMUNE HEPATITIS; BILE DUCT CARCINOMA; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CYSTITIS; DIABETES CONTROL; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MALE; MIDDLE AGED; MYALGIA; NAUSEA; PRIORITY JOURNAL; RECURRENT INFECTION; REMISSION; RESPIRATORY TRACT CYSTITIS; SCALP PRURITUS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; YOUNG ADULT; ANALOGS AND DERIVATIVES; BLOOD; HEPATITIS, AUTOIMMUNE; IMMUNOLOGY; LIVER FUNCTION TEST; MULTIDRUG RESISTANCE; TERTIARY CARE CENTER; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; ALANINE TRANSAMINASE; AZATHIOPRINE; DRUG RESISTANCE, MULTIPLE; EVEROLIMUS; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; REMISSION INDUCTION; TERTIARY CARE CENTERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929894634     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.998271     Document Type: Article

References (50)

1. Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980;21:78-83.
2. Hoeroldt B, McFarlane E, Dube A, Basumani P, Karajeh M, Campbell MJ, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011;140:1980-9.
3. Miyake Y, Iwasaki Y, Terada R, Okamaoto R, Ikeda H, Makino Y, et al. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006;24:1197-205.
4. Tan P, Marotta P, Ghent C, Adams P. Early treatment response predicts the need for liver transplantation in autoimmune hepatitis. Liver Int 2005;25:728-33.
5. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993;342:273-5.
6. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004;2:625-31.
7. Miyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Sakai N, et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther 2006;23:1347-53.
8. Ichai P, Duclos-Vallee JC, Guettier C, Hamida SB, Antonini T, Delvart V, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007;13:996-1003.
9. Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology 2007;46:1828-35.
10. Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 2009;29:816-23.
11. Kanzler S, Lohr H, Gerken G, Galle PR, Lohse AW. Longterm management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol 2001;39: 339-8.
12. Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980;21:78-83.
13. Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitnick GL, Elveback IR, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972;63:820-33.
14. Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975;16:876-83.
15. Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitnick GL, Elveback IR, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972;63:820-33.
16. Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010;139: 1198-206.
17. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004;38:805-9.
18. Baven-Pronk AM, Coenraad MJ, van Buuren HR, de Man RA, van Erpecum KJ, Lamers MM, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther 2011;34:335-43.
19. Chatur N, Ramji A, Bain VG, Ma MM, Marotta PJ, Ghent CN, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005;25: 723-7.
20. Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987;93:890-3.
21. Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel HB. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007;13:3232-6.
22. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33:371-5.
23. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol 2011;55: 636-46.
24. Hennes EM, Oo YH, Schramm C, Denzer U, Buggisch P, Wiegard C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008;103:3063-70.
25. Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel HB. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007;13:3232-6.
26. Sharzehi K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol 2010;24:588-92.
27. TannousMM, Cheng J, Muniyappa K, Farooq I, Bharara A, Kappus M, et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther 2011;34:405-7.
28. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol 2011;55:636-46.
29. Hlivko JT, Shiffman ML, Stravitz RT, Luketic VA, Sanyal AJ, Fuchs M, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008;6:1036-40.
30. Inductivo-Yu I, Adams A, Gish RG, Wakil A, Bzowej NH, Frederick RT, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007;5:799-802.
31. Kerkar N, Dugan C, Rumbo C, Morotti RA, Gondolesi G, Shneider BL, et al. Rapamycin successfully treats posttransplant autoimmune hepatitis. Am J Transplant 2005;5: 1085-9.
32. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
33. Kanzler S, Lohr H, Gerken G, Galle PR, Lohse AW. Longterm management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol 2001;39: 339-8.
34. Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980;21:78-83.
35. Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007;27:507-15.
36. Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitnick GL, Elveback IR, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972;63:820-33.
37. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998;29:990-3.
38. Kanzler S, Gerken G, Dienes HP, Meyer zum Buschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis-report of three cases. Z Gastroenterol 1997;35:571-8.
39. Perez-Alvarez R, Perez-de-Lis M, Ramos-Casals M. Biologics-induced autoimmune diseases. Curr Opin Rheumatol 2013;25:56-64.
40. Weiler-Normann C, Schramm C, Quaas A, Wiegard C, Glaubke C, Pannicke N, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol 2013;58:529-34.
41. Vallin M, Guillaud O, Morard I, Gagnieu MC, Mentha G, Adham M, et al. Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients. Clin Transplant 2011;25:660-9.
42. Budde K, Neumayer HH, Lehne G, Winkler M, Hauser IA, Lison A, et al. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients. Nephrol Dial Transplant 2004;19:2606-14.
43. Anandappa G, Hollingdale A, Eisen T. Everolimus- A new approach in the treatment of renal cell carcinoma. Cancer Manag Res 2010;2:61-70.
44. Langer RM, Hene R, Vitko S, Christiaans M, Tedesco-Silva H Jr, Ciechanowski K, et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, openlabel, multicentre trial in renal transplantation. Transpl Int 2012;25:592-602.
45. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet 2008;372:449-56.
46. Langer RM, Hene R, Vitko S, Christiaans M, Tedesco-Silva H Jr, Ciechanowski K, et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, openlabel, multicentre trial in renal transplantation. Transpl Int 2012;25:592-602.
47. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet 2008;372:449-56.
48. Bilbao I, Sapisochin G, Dopazo C, Lazaro JL, Pou L, Castells L, et al. Indications and management of everolimus after liver transplantation. Transplant Proc 2009;41:2172-6.
49. Kawahara T, Asthana S, Kneteman NM. m-TOR inhibitors: what role in liver transplantation? JHepatol 2011;55:1441-51.
50. Houghton PJ.Everolimus. Clin Cancer Res 2010;16:1368-72.